For the first time, the World Health Organization has sanctioned use of a generic hepatitis C medicine by the United Nations and other agencies in hopes of widening access to a needed treatment.

Specifically, the WHO wants to encourage greater use of lower-cost versions of Sovaldi in dozens of countries where public health advocates say availability has been impeded by bureaucratic delays to an access plan hatched three years ago by Gilead Sciences, which sells the brand-name drug.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Stylish new page look, I see? Meanwhile, that’s quite a price adjustment – $3/USD per pill, down from $1,000 USD. And Mylan will still make money? Or will they be relying on the EpiPen to make up the difference?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy